The intracellular site of virus-specific DNA synthesis was studied in mouse 3T6 cells early after efficient infection with the Harvey strain of murine sarcoma-leukemia virus. Treatment of cells with arabinosyl cytosine at different times after infection indicated that DNA synthesis at 1–4 h was essential for both the subsequent transcription of virus-specific RNA and the formation of progeny virus. Autoradiographic analysis of cells pulse-labeled with tritiated thymidine at different times after infection showed that DNA synthesis begins in the cytoplasm within 1 h after infection, reaches a maximal rate at 2 h, and decreases subsequently. Newly synthesized cytoplasmic DNA is rapidly transported to the nucleus, as indicated by autoradiographs of cells irradiated with ultraviolet light to block cell DNA synthesis, then infected with virus, pulse-labeled with tritiated thymidine and chased with unlabeled thymidine. The viral nature of newly synthesized cytoplasmic DNA was demonstrated by the isolation of labeled DNA from the cytoplasmic fraction at different times after infection that hybridized with viral 60–70S RNA.

Keywords:
MSV(MLV) DNA, Cytoplasmic DNA
This content is only available via PDF.
© 1974 S. Karger AG, Basel
1974
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.